Sterling Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Sterling Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.66M	Sell	13,727 -1,202	-8%	-$281K	0.06%	240
2026 Q1	$3.41M	Sell	14,929 -9,880	-40%	-$2.21M	0.06%	231
2025 Q4	$5.29M	Buy	24,809 +25	+0.1%	+$5.16K	0.09%	188
2025 Q3	$4.93M	Sell	24,784 -29,725	-55%	-$5.54M	0.07%	190
2025 Q2	$9.41M	Buy	54,509 +3,432	+7%	+$559K	0.13%	104
2025 Q1	$7.96M	Sell	51,077 -5,773	-10%	-$825K	0.12%	104
2024 Q4	$7.83M	Buy	56,850 +9,065	+19%	+$1.19M	0.11%	120
2024 Q3	$7.13M	Buy	+47,785	New	+$6.45M	0.09%	148
2019 Q3	$5.83M	Buy	60,580 +5,830	+11%	+$650K	0.06%	228
2019 Q2	$6.3M	Buy	54,750 +12,790	+30%	+$1.53M	0.06%	228
2019 Q1	$4.94M	Buy	+41,960	New	+$3.67M	0.05%	244
2015 Q2	–	Sell	-19,452	Closed	-$337K	–	879
2015 Q1	$337K	Buy	+19,452	New	+$354K	﹤0.01%	768

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sterling Capital Management's ASND Position: Q2 2026 in Review

Sterling Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 8.1% in Q2 2026, selling an estimated $281K and leaving 13,727 shares worth $3.66M. The position accounts for 0.06% of the portfolio, ranked #240.

Sterling Capital Management first reported a position in ASND in Q1 2015 and has held it in 12 quarters since. The position peaked at $9.41M in Q2 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Sterling Capital Management held 13,727 shares of Ascendis Pharma A/S worth $3.66M as of Q2 2026.
Sterling Capital Management sold 1,202 Ascendis Pharma A/S shares in Q2 2026, an estimated $281K.
Ascendis Pharma A/S made up 0.06% of Sterling Capital Management's portfolio in Q2 2026, its #240 holding.
Sterling Capital Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 12 quarters since.
Sterling Capital Management's Ascendis Pharma A/S position peaked at $9.41M in Q2 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.